drugset
Drugs / Urokinase-Derived Peptide A6
last change Jul 2012 re-read 3 minutes ago

Urokinase-Derived Peptide A6

Peptide

Developed for
fallopian tube carcinoma · ovarian Brenner tumor · ovarian clear cell cystadenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian mucinous cystadenocarcinoma · ovarian serous cystadenocarcinoma · primary peritoneal carcinoma · undifferentiated ovarian carcinoma
Investigated by
Gynecologic Oncology Group · National Cancer Institute (NCI)

Trials 1

today NCT00939809 · Ph 2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00939809 Jul 2009 → Jul 2012 fallopian tube carcinoma, ovarian Brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma +4 Gynecologic Oncology Group Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Urokinase-Derived Peptide A6 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00939809 ↗
Modality Peptide “Urokinase-Derived Peptide A6” NCT00939809 ↗
Route Subcutaneous “A6 subcutaneously once daily” NCT00939809 ↗